OCGN Ocugen, Inc.

0.3
-0.05  -14%
Previous Close 0.35
Open 0.35
Price To Book -1.2
Market Cap 15,782,306
Shares 52,625,228
Volume 3,231,590
Short Ratio
Av. Daily Volume 3,021,472
Stock charts supplied by TradingView

NewsSee all news

  1. Ocugen Provides Business Update and Full Year 2019 Financial Results

    Over 95% planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020 Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., March 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc.

  2. Ocugen to Host Conference Call on Friday, March 27 at 8:30 a.m. ET to Discuss 2019 Financial Results and Provide Business Update

    MALVERN, Pa., March 20, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved

  3. Nature Gene Therapy Publishes Preclinical Data of Ocugen's OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

    MALVERN, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved

  4. Ocugen to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference

    MALVERN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved

  5. Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD

    MALVERN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), ), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data due 2H 2020..
OCU 300
Graft Versus Host Disease

Latest News

  1. Ocugen Provides Business Update and Full Year 2019 Financial Results

    Over 95% planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020 Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., March 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc.

  2. Ocugen to Host Conference Call on Friday, March 27 at 8:30 a.m. ET to Discuss 2019 Financial Results and Provide Business Update

    MALVERN, Pa., March 20, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved

  3. Nature Gene Therapy Publishes Preclinical Data of Ocugen's OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

    MALVERN, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved

  4. Ocugen to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference

    MALVERN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved

  5. Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD

    MALVERN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), ), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  6. Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights

    MALVERN, Pa., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  7. Ocugen Announces Warrant Restructuring

    MALVERN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  8. Ocugen Announces Appointments to Retina Disease and Ocular Graft-Versus-Host Disease Scientific Advisory Boards

    MALVERN, Pa., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  9. Ocugen to Host Conference Call on Friday, November 8 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

    MALVERN, Pa., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  10. Ocugen Announces Share Repurchase Program

    MALVERN, Pa., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN) today announced that its Board of Directors unanimously approved a share repurchase program authorizing the repurchase of up to $2 million in

  11. Ocugen Announces Amendment to Asset Purchase Agreement

    MALVERN, Pa., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN) a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that

  12. Ocugen Appoints Sanjay S. Subramanian, MBA, as Chief Financial Officer

    MALVERN, Pa., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ:OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that